New drug combo aims to halt debilitating nerve damage
NCT ID NCT05065554
Summary
This study is testing whether combining the drug acalabrutinib with an antibody treatment (like rituximab) is safe and effective for people with nerve damage (neuropathy) caused by specific blood conditions. The goal is to control the underlying disease and improve or stabilize nerve symptoms like weakness, numbness, and walking problems. About 33 participants will receive the treatment for up to four years and be followed for two more.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROPATHY;PERIPHERAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.